Positive and Negative Predictive Factors for Treatment Response in Patients with Chronic Viral C Hepatitis

Overview

Journal Curr Health Sci J

Specialty General Medicine

Date 2019 Jan 1

PMID 30595896

Authors

Adina Maria Kamal

P Mitrut

Alexandra Dana Ciobanu

C K Kamal

Oana Sorina Tica

A A Tica

Affiliations

Soon will be listed here.

Abstract

More than 200 million people worldwide are infected with hepatitis C virus. In the United States, suggested estimates are that more than 5 million people live with HCV. The purpose of this paper is to identify, within the Southwestern Romanian population, host factors associated with the response to Pegylated Interferon and Ribavirin treatment for Hepatitis C virus infection. We investigated several factors and their correlation to sustained virological response. The study included 267 patients diagnosed with chronic Hepatitis C between 2013 and 2016, treated with Pegylated Interferon and Ribavirin in the 2nd Medical Department of the Emergency County Hospital Craiova. From the 267 patients included in this study, 149 (55,81%) achieved sustained virological response during the 48 weeks of treatment. Several factors were taken in consideration regarding the treatment response. Positive predictive factors for achieving sustained virological response were: the female gender (35,96%), Low Viral Load at the beginning of treatment, Early Virological Response 75 (28,09%), Rapid Virologic Response133 (49,81%), and stage of fibrosis, with Stage F1 having the highest rate of Sustained Virological Response during double therapy 81 (30,34%). Although at the present time a number of more effective antiviral products have been approved for the treatment of viral hepatitis C, in our country the standard of treatment remains with PegInterferon and Ribavirin therapy. Multiple clinical and paraclinical tools can identify patients with a high chance of responding to treatment, or those who, during treatment, do not meet the criteria for prolonging therapy.

References

Kuboki M, Shinzawa H, Shao L, Ishibashi M, YOSHII E, Suzuki K . A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver. 1999; 19(2):88-96. DOI: 10.1111/j.1478-3231.1999.tb00016.x. View

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

Campello C, Poli A, Dal M . Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection. 2002; 30(1):7-12. DOI: 10.1007/s15010-001-1197-4. View

Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales Jr F . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. DOI: 10.1056/NEJMoa020047. View

Evans J, Hahn J, Page-Shafer K, Lum P, Stein E, Davidson P . Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003; 80(1):137-46. PMC: 3456106. DOI: 10.1093/jurban/jtg137. View

Pawlotsky J . Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis. 2003; 7(1):45-66. DOI: 10.1016/s1089-3261(02)00065-x. View

Seeff L, Hoofnagle J . Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003; 7(1):261-87. DOI: 10.1016/s1089-3261(02)00078-8. View

Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J . Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38(3):645-52. DOI: 10.1053/jhep.2003.50364. View

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

10.

Nguyen M, Keeffe E . Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005; 3(10 Suppl 2):S97-S101. DOI: 10.1016/s1542-3565(05)00711-1. View

11.

Grigorescu M . HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2009; 18(1):45-50. View

12.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M . Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9):1259-69. PMC: 3071938. DOI: 10.1111/j.1478-3231.2010.02283.x. View

13.

Swain M, Lai M, Shiffman M, Cooksley W, Zeuzem S, Dieterich D . A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 139(5):1593-601. DOI: 10.1053/j.gastro.2010.07.009. View

14.

Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R . FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. J Hepatol. 2010; 54(2):227-35. DOI: 10.1016/j.jhep.2010.06.038. View

15.

Lavanchy D . Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2010; 17(2):107-15. DOI: 10.1111/j.1469-0691.2010.03432.x. View

16.

Mohd Hanafiah K, Groeger J, Flaxman A, Wiersma S . Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2012; 57(4):1333-42. DOI: 10.1002/hep.26141. View

17.

van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F . Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24):2584-93. DOI: 10.1001/jama.2012.144878. View

18.

Manns M, Pockros P, Norkrans G, Smith C, Morgan T, Haussinger D . Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat. 2013; 20(8):524-9. DOI: 10.1111/jvh.12074. View

19.

Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili L, Menniti-Ippolito F . Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997; 26(4):1006-11. DOI: 10.1002/hep.510260431. View